10.6084/m9.figshare.c.3806578_D3.v1 Melissa García-Caballero Melissa García-Caballero Jenny Paupert Jenny Paupert Silvia Blacher Silvia Blacher Maureen Van de Velde Maureen Van de Velde Ana Quesada Ana Quesada Miguel Medina Miguel Medina Agnès Noël Agnès Noël Additional file 3: Figure S3. of Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases Springer Nature 2017 AD0157 Lymphangiogenesis VEGFR-3/-2 Lymph nodes Lymphatic metastasis 2017-06-19 05:00:00 Dataset https://springernature.figshare.com/articles/dataset/Additional_file_3_Figure_S3_of_Targeting_VEGFR-3_-2_signaling_pathways_with_AD0157_a_potential_strategy_against_tumor-associated_lymphangiogenesis_and_lymphatic_metastases/5122225 AD0157 inhibits LEC and MDA-MB-231/Luc+ cell proliferation. Representative curves showing the dose-dependent effect of AD0157 on the in vitro growth of LEC and MDA-MB-231/Luc+ cells. Cell proliferation is represented as a percentage of untreated cells. Each point represents the mean of quadruplicates; SD values were typically lower than 10% of the mean values and are omitted for clarity. The half-maximal inhibitory concentration (IC50) value was calculated from dose-response curves as the concentration of compound yielding 50% of control cell survival. It is expressed as means ± s.e.m. of five independent experiments. (PS 415 kb)